Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

56
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
56
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

660
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
660
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

849
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
849
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

642
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
642

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-Density Lipoprotein Cholesterol and Dementia Risk: Integrating Mendelian Randomization and Target Trial Emulation Within the Heart-Brain Axis.

medRxiv : the preprint server for health sciences·2026
Same author

CKM Multimorbidity Burden and Phenotype Differentially Influence Cardiovascular and Renal Risk in Advanced CKD.

Cardiorenal medicine·2026
Same author

Beyond eGFR and Albuminuria: Biological Pathways and Multiomics in Cardiovascular-Kidney-Metabolic Disease.

Kidney international reports·2026
Same author

Metabolic syndrome and kidney dysfunction: emerging molecular and cellular mechanisms at the metabolic-renal interface.

Frontiers in endocrinology·2026
Same author

Updated BJP guidelines for transparent and rigorous natural product research.

British journal of pharmacology·2026
Same author

Automating the quality monitoring of a hospital discharge summary improvement project utilising large language models.

NPJ digital medicine·2026
Same journal

Re-thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics.

British journal of pharmacology·2026
Same journal

Tangeretin ameliorates sepsis-induced neurocognitive impairment in adult male mice by suppressing Akt-driven glycolytic reprogramming and neuroinflammation.

British journal of pharmacology·2026
Same journal

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having 'bifunctional' bronchodilator and anti-inflammatory activity.

British journal of pharmacology·2026
Same journal

Glucagon-like peptide-1 improves vascular endothelial dysfunction in hypertensive mice via CREB-driven transcriptional regulation of long non-coding RNA 155383.

British journal of pharmacology·2026
Same journal

The chemokine receptor-like fourth extracellular loop of the apelin receptor differentially regulates apelin and elabela binding and signalling.

British journal of pharmacology·2026
Same journal

Peripheral targets for neuropathic pain.

British journal of pharmacology·2026
See all related articles

Related Experiment Video

Updated: Sep 19, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.5K

Advancing antihypertensive drug development.

Fay Pu1, Yanrong Liu2, Fozia Zahir Ahmed3

  • 1Intensive care units, University Hospitals of Morecambe Bay NHS Foundation Trust, Kendal, UK.

British Journal of Pharmacology
|June 3, 2025
PubMed
Summary
This summary is machine-generated.

Innovative hypertension treatments like aldosterone synthase inhibitors and RNA-based therapies offer improved blood pressure control and cardiorenal benefits. These novel strategies target underlying mechanisms to overcome resistance and enhance patient outcomes.

Keywords:
endothelin receptor antagonistshypertensionmineralocorticoid receptor antagonist

More Related Videos

Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

7.6K
Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
10:09

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound

Published on: August 4, 2022

3.3K

Related Experiment Videos

Last Updated: Sep 19, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.5K
Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

7.6K
Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
10:09

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound

Published on: August 4, 2022

3.3K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Nephrology

Background:

  • Hypertension impacts over a billion people globally, causing significant cardiovascular issues.
  • Current treatments face challenges like resistance, side effects, and poor adherence, hindering optimal blood pressure control.

Purpose of the Study:

  • To review innovative therapeutic strategies for managing hypertension.
  • To explore novel approaches addressing treatment resistance, adverse effects, and adherence challenges.

Main Methods:

  • Review of emerging pharmacological agents including aldosterone synthase inhibitors, mineralocorticoid receptor antagonists, and endothelin receptor antagonists.
  • Analysis of novel therapeutic modalities such as RNA-based therapies (e.g., zilebesiran), AT2 receptor agonists, ACE2 activators, and NAD+ boosting compounds.
  • Discussion of supportive strategies like gut microbiome modulation and fixed-dose combination pills.

Main Results:

  • Aldosterone synthase inhibitors and non-steroidal mineralocorticoid receptor antagonists demonstrate improved blood pressure control with enhanced cardiorenal protection and reduced hyperkalemia risk.
  • Endothelin receptor antagonists show potential for treating resistant hypertension by targeting vasoconstriction.
  • RNA-based therapies, such as zilebesiran, offer sustained blood pressure reduction via angiotensinogen suppression with infrequent dosing.

Conclusions:

  • Emerging therapies target specific pathophysiological pathways for a precision-focused approach to hypertension management.
  • Novel strategies promise to improve blood pressure control, reduce the global burden of hypertension, and enhance patient outcomes.
  • Future research and clinical application of these innovations are crucial for advancing hypertension care.